bexarotene has been researched along with Carcinoma, Papillary in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| French, J; Haugen, B; Jimeno, A; Kane, M; Klopper, J; Pike, L; Sams, S; Tompkins, K | 1 |
| Corssmit, EP; Liu, YY; Morreau, HA; Pereira, AM; Romijn, JA; Smit, JW; Stokkel, MP | 1 |
2 trial(s) available for bexarotene and Carcinoma, Papillary
| Article | Year |
|---|---|
A Phase II Trial of Bexarotene for Advanced Differentiated Thyroid Cancer.
Topics: Adenocarcinoma, Follicular; Aged; Anticarcinogenic Agents; Bexarotene; Carcinoma, Papillary; Female; Humans; Male; Middle Aged; Tetrahydronaphthalenes; Thyroid Neoplasms; Treatment Outcome | 2015 |
Bexarotene increases uptake of radioiodide in metastases of differentiated thyroid carcinoma.
Topics: Adult; Aged; Bexarotene; Carcinoma, Papillary; Cell Differentiation; Female; Humans; Iodine Radioisotopes; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Recombinant Proteins; Retinoid X Receptors; Tetrahydronaphthalenes; Thyroid Neoplasms; Thyroidectomy; Thyrotropin; Thyroxine; Triiodothyronine | 2006 |